CareDx, Inc (CDNA) Investor Relations Documents

CareDx, Inc (CDNA) investor relations documents from the company's IR site: 5 presentations, 34 press releases; latest deck 2026-07-30. Read in-app with summaries. First-party data.

Presentation: CareDx Q2 2026 financial results show $132M in total revenue, a 52% YoY increase, driven by strong transplant testing volume and strategic portfolio optimization.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-07Press releaseCareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-31Press releaseCareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-30Press releaseCareDx Announces Second Quarter 2026 Financial Results
2026-07-30PresentationPresentation
2026-07-30Press releaseCareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
2026-07-16Press releaseCareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
2026-07-16Press releaseCareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
2026-07-01Press releaseCareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
2026-06-30Press releaseCareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
2026-06-18Press releaseCareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Trans
2026-06-16Press releaseCareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
2026-05-20Press releaseCareDx to Participate in Upcoming Investor Conferences
2026-05-11Press releaseCareDx Announces Dismissal of 2021 Qui Tam Suit
2026-05-01Press releaseCareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-28Press releasePress Release of Q1 2026, aspx file, (opens in new window)
2026-04-28Press releaseCareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
2026-04-28Earnings deckPresentation of Q1 2026, PDF file, (opens in new window)
2026-04-28Press releaseDownload (opens in new window)
2026-04-24ESG reportESG Report of 2025, PDF file, (opens in new window)
2026-04-23Press releaseCareDx Announces Dismissal of 2021 Qui Tam Suit
2026-04-21Press releaseCareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for
2026-04-20Press releaseCareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
2026-04-15Press releaseCareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Qu
2026-04-14Press releaseCareDx to Report First Quarter 2026 Financial Results on April 28, 2026
2026-02-27Press releaseCareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-24Press releasePress Release
2026-02-24Press releaseCareDx Announces Fourth Quarter and Full Year 2025 Financial Results
2026-02-24Press releaseCareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer
2026-02-24Earnings deckCareDx 2025 Q4 and Full Year Financial Results Conference Call
2026-02-18Press releaseCareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
2026-02-12Press releaseCareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and M
2026-02-12PresentationAlloHeme™ Clinical Validation Data Review and Launch Timeline
2026-02-10Press releaseCareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
2026-02-03Press releaseCareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meet
2026-01-27Press releaseCareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2026-01-12Press releaseCareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
2025-12-26Press releaseCareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-07Press releaseCareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-06Press releaseCareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
2025-11-04PresentationPresentation

CDNA overview · CDNA earnings · CDNA financials · CDNA KPIs · CDNA documents · CDNA ownership · CDNA peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.